Phase III Trial of Adjuvant Chemo-radiotherapy After D2 Surgery of Gastric Cancer
The purpose of this study is to explore the efficacy of adjuvant radiotherapy for D2 resected gastric cancer
Gastric Cancer
RADIATION: Concurrent chemo-radiotherapy|DRUG: Chemotherapy
DFS, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months, 36 months
OS, From date of randomization until the date of first documented death from any cause, assessed up to 36 months, 36 months
The radiotherapy dose of 45Gy in 25 fractions as adjuvant treatment after D2 surgery for gastric cancer